COVID-19 Pandemic Leads to Radiotherapy Interruptions in China
More than half of patients could not receive radiotherapy after the lockdown in Wuhan, China.
Radiotherapy
Prostate Cancer Treatment Side Effects Worse With Prostatectomy
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
Ultrahypofractionated SBRT Prostate Cancer Radiotherapy Does Not Increase Radiotoxicities
Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.
Clinical Missteps Obscuring a Lung Cancer Diagnosis
Although the rate of cancer misdiagnosis is quite high across malpractice claims, this number does not necessarily correlate with what occurs in clinical practice, an expert warned.
Radiation Therapy After Prostate Surgery Offers No Benefit
Study findings suggest that many men can be spared radiation therapy following radical prostatectomy for high-risk prostate cancer.
Radio-Enhancing Nanoparticles in Sarcoma: Readout of Clinical Outcomes Expected by 2020
Radiation-enhancing particles appear to be a promising tool for improving results with radiotherapy — perhaps even across various cancers.
Surgery May Be Best Option for High-Risk Prostate Cancer With Low PSA
In a study of men with Gleason 8 to 10 prostate cancer and low PSA, radical prostatectomy was associated with better survival odds than external beam radiation therapy with or without brachytherapy.
Study Supports Ultra-Hypofractionated Radiotherapy for Prostate Cancer
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
False-Positive PET Leads to Unneeded Workup for Hodgkin Lymphoma Patient
A classic Hodgkin lymphoma patient had a false-positive PET, leading to unneeded workup.
Study Predicts Important Role for SABR in Treatment of Early-stage NSCLC
SABR may be used to improve PFS, or potentially OS, among patients who have a good response to chemotherapy, targeted therapy, or immunotherapy.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...